Abstract：
Giant cell arteritis (GCA), more common in Northern European populations, has limited data in Arabcountries. Our study reports GCA\'s clinical manifestations in Jordan and reviews published research on GCA across Arab nations. In this retrospective analysis, GCA patients diagnosed from January 2007 to March 2019 at a Jordanian academic medical center were included through referrals for temporal artery biopsy (TAB). A comprehensive search in PubMed, Scopus, and the DOAJ (Directory of Open Access Journals) databases was conducted to identify all relevant English-language manuscripts from Arab countries on GCA without time limitations. Among 59 diagnosed GCA patients, 41 (69.5%) were clinically diagnosed with a negative TAB, and 19 (30.5%) had a positive result. Females comprised 74.6% (n = 44) with 1:3 male-female ratio. The mean age at diagnosis was 67.3 (± 9.5) years, with most presenting within two weeks (n = 40, 67.8%). Headache was reported by 54 patients (91.5%). Elevated ESR occurred in 51 patients (78%), with a mean of 81 ± 32.2 mm/hr. All received glucocorticoids for 13.1 ± 10 months. Azathioprine, Methotrexate, and Tocilizumab usage was 15.3% (n = 9), 8.5% (n = 5), and 3.4% (n = 2), respectively. Remission was observed in 57.6% (n=34), and 40.7% (n = 24) had a chronic clinical course on treatment. Males had higher biopsy-based diagnoses (p = .008), and biopsy-diagnosed patients were older (p = .043). The literature search yielded only 20 manuscripts originating in the Arab world. The predominant study types included case reports and retrospective analyses, with only one case series and onecase-control study.
摘要：
巨细胞动脉炎(GCA),在北欧人口中更常见，在阿拉伯国家的数据有限。我们的研究报告了约旦GCA的临床表现，并回顾了阿拉伯国家已发表的GCA研究。在这个回顾性分析中,2007年1月至2019年3月在约旦学术医学中心诊断的GCA患者通过推荐颞动脉活检（TAB）纳入。在PubMed中进行全面搜索,Scopus,并进行了DOAJ（开放获取期刊目录）数据库，以识别阿拉伯国家在GCA上的所有相关英语手稿，而没有时间限制。在59名确诊的GCA患者中，41例(69.5%)临床诊断为TAB阴性，19例(30.5%)阳性结果。女性占74.6%(n=44)，男女比例为1:3。诊断时的平均年龄为67.3（±9.5）岁，大多数在两周内出现（n=40，67.8%）。54例患者报告头痛（91.5%）。ESR升高的患者有51例（78%），平均值为81±32.2mm/hr。所有患者均接受糖皮质激素治疗13.1±10个月。硫唑嘌呤,甲氨蝶呤,Tocilizumab的使用率为15.3%（n=9），8.5%(n=5)，和3.4%(n=2)，分别。缓解率为57.6%(n=34)，40.7％（n=24）有慢性临床疗程。男性的活检诊断更高（p=0.008），活检诊断的患者年龄较大（p=.043）。文献检索仅产生了20份起源于阿拉伯世界的手稿。主要研究类型包括病例报告和回顾性分析，只有一个病例系列和一次性对照研究。
